Dimensional Fund Advisors LP Has $230.80 Million Holdings in Laboratory Corp. of America Holdings (LH)

Dimensional Fund Advisors LP lowered its position in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 0.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,426,913 shares of the medical research company’s stock after selling 537 shares during the period. Dimensional Fund Advisors LP owned about 1.40% of Laboratory Corp. of America worth $230,801,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. grew its stake in Laboratory Corp. of America by 2.0% in the fourth quarter. BlackRock Inc. now owns 7,970,872 shares of the medical research company’s stock valued at $1,271,436,000 after purchasing an additional 159,639 shares during the last quarter. Boston Partners grew its stake in Laboratory Corp. of America by 7.8% in the first quarter. Boston Partners now owns 5,673,767 shares of the medical research company’s stock valued at $917,732,000 after purchasing an additional 409,742 shares during the last quarter. UBS Asset Management Americas Inc. grew its stake in Laboratory Corp. of America by 6.6% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,787,460 shares of the medical research company’s stock valued at $285,118,000 after purchasing an additional 110,625 shares during the last quarter. Iridian Asset Management LLC CT grew its stake in Laboratory Corp. of America by 4.5% in the first quarter. Iridian Asset Management LLC CT now owns 1,690,921 shares of the medical research company’s stock valued at $273,506,000 after purchasing an additional 72,695 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Laboratory Corp. of America by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 1,117,429 shares of the medical research company’s stock valued at $177,887,000 after purchasing an additional 35,722 shares during the last quarter. Hedge funds and other institutional investors own 92.30% of the company’s stock.

Shares of LH stock opened at $187.88 on Friday. Laboratory Corp. of America Holdings has a fifty-two week low of $140.03 and a fifty-two week high of $190.35. The stock has a market cap of $19.25 billion, a PE ratio of 19.57, a price-to-earnings-growth ratio of 1.66 and a beta of 0.93. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.27 and a current ratio of 1.38.



Laboratory Corp. of America (NYSE:LH) last issued its quarterly earnings results on Wednesday, April 25th. The medical research company reported $2.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.63 by $0.15. Laboratory Corp. of America had a return on equity of 16.33% and a net margin of 11.52%. The business had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.77 billion. During the same quarter in the previous year, the firm earned $2.22 earnings per share. The company’s revenue was up 18.0% on a year-over-year basis. sell-side analysts predict that Laboratory Corp. of America Holdings will post 11.56 EPS for the current year.

In related news, insider Lisa J. Uthgenannt sold 4,500 shares of Laboratory Corp. of America stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $182.10, for a total transaction of $819,450.00. Following the completion of the sale, the insider now owns 3,755 shares of the company’s stock, valued at $683,785.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Edward T. Dodson sold 13,000 shares of Laboratory Corp. of America stock in a transaction dated Wednesday, June 6th. The stock was sold at an average price of $183.35, for a total value of $2,383,550.00. Following the sale, the insider now directly owns 22,113 shares of the company’s stock, valued at approximately $4,054,418.55. The disclosure for this sale can be found here. Insiders have sold 179,010 shares of company stock valued at $30,604,044 in the last ninety days. Corporate insiders own 0.73% of the company’s stock.

Several equities analysts have issued reports on LH shares. Barclays lifted their target price on Laboratory Corp. of America from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 25th. Zacks Investment Research lowered Laboratory Corp. of America from a “buy” rating to a “hold” rating in a research note on Monday, April 30th. Argus started coverage on Laboratory Corp. of America in a research note on Friday, March 23rd. They issued a “buy” rating and a $202.00 target price on the stock. Morgan Stanley lifted their target price on Laboratory Corp. of America from $182.00 to $192.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $176.00 target price on shares of Laboratory Corp. of America in a research note on Tuesday, March 6th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $192.18.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply